SLC5A2 and prediabetes syndrome: A randomized, double-blind trial enrolling 40 patients with prediabetes showed that an 8-week treatment with empagliflozin was able to restore brain insulin sensitivity compared with placebo, which may contribute to the beneficial effects of SGLT-2 inhibitors [50].